March 22, 2024
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer(Securities Code: 4582)

Notice of Appointments to the Board Directors and substitute member of the Audit &Supervisory Committee, and Appointments of Corporate Officers
TOKYO, Japan, March 22, 2024 - SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today
announced appointments to its Board Directors (excluding directors who are members of the Audit &Supervisory Committee), Board of Directors who are members of the Audit & Supervisory Committee andone substitute member of the Audit & Supervisory Committee made by resolution of shareholders
approved at the 19th Annual General Meeting of Shareholders (the “AGM”), and Representative
Director and Corporate Officer appointments approved by the Board of Directors at a board meeting
convened following the close of the AGM. The appointments are as follows:
1.

Board Directors (excluding directors who are Audit and Supervisory Committee members)
Name

2.

Fuminori Yoshida

Representative Director

Shigetoshi Matsumoto
Bruce David Cheson
Eiji Ebinuma
Toshio Imabeppu (newly appointed)
George Morstyn (newly appointed)

Board Director <Outside>
Board Director <Outside>
Board Director <Outside>
Board Director <Outside>
Board Director <Outside>

Board Directors who are members of the Audit & Supervisory Committee
NameKiyoshi Watanabe
Kesao Endo
Yasuhiro Tamou

3.

Title

Title
Board Director, Full-Time Audit & Supervisory
Committee Member <Outside>
Board Director, Audit & Supervisory Committee
Member <Outside>
Board Director, Audit & Supervisory Committee
Member <Outside>

Substitute Member of the Audit & Supervisory Committee
NameTakashi Watanabe

Title
Substitute Member of the Audit & Supervisory
Committee <Outside>

14.

Corporate Officers
NameTitle
President and Chief Executive Officer

Fuminori Yoshida

Executive Vice President, Corporate Officer, Chief
Financial Officer
Executive Corporate Officer
Corporate Officer

Takaaki Fukushima
Shunichi Sasaki (newly appointed)
Hiroyuki Horita

The biographies of the two new directors and a corporate officer are as follows:
New DirectorCareer

Toshio Imabeppu
Apr., 1981
Oct., 1988
Aug., 2002
Jul., 2004
Jul., 2008
Jul., 2013
Jul., 2014
Oct., 2015
Jun., 2019
Jun., 2022
Jun., 2022
Mar., 2024

New DirectorCareerEntered Ministry of Health and Welfare (currentlyMinistry of Health, Labor and Welfare)
OfficeofAdvanced

PharmaceuticalTechnology

Promotion, Ministry of Health, Labour and Welfare
Cabinet Counselor, Cabinet Secretariat
Director, Insurance Division, Ministry of Health, Labourand Welfare
Director, Accounting Division, Ministry of FinanceDirector General, Pharmaceutical and Food Safety
Bureau, Ministry of Health, Labour and Welfare
Director for Policy Management, Ministry of Foreign
Affairs of Japanretirement from MHLW
Outside Director of Ship Healthcare Holdings HD(concurrent)
Chairman of the Board of Directors, Japan Association
for Regenerative Medicine (concurrent)
Representative Director, Judo Therapy Training andExamination Foundation (concurrent)
SymBio Pharmaceuticals Outside Director

George MorstynMar., 1991

Senior Vice President,
Global Development and CMO, Amgen Inc.

Apr., 2006

CEO, G&R Morstyn Party Limited (concurrent)

Mar., 2009

Appointed as SymBio Pharmaceuticals Outside Director

Jul., 2010

Vice Chair, Victorian Comprehensive Cancer Centre,Australia

2Dec., 2017
Mar., 2019
May, 2021
Mar., 2024

External Director of Actinogen Medical (Australia) Pty
Ltd (concurrent)
Resignation from SymBio Pharmaceuticals Outside
Director
Chairman of the Board of Directors, PioTx, Australia(concurrent)
SymBio Pharmaceuticals Outside Director

New CorporateShunichi SasakiOfficerCareer
Tokyo University of Pharmacy and Life ScienceMar., 1996Mar., 1998
Apr., 1998

(Chemistry)
Graduate School Tokyo University of Pharmacy and Life
Science Graduated with Master of Science
DAIICHI PHARMACEUTICAL CO., LTD.
PL/ APL/ CRA, Clinical Development, R&D DivisionNov., 2006

Associate Director, Clinical Development, DAIICHISANKYO PHARMA DEVELOPMENT, USA (seconded)Mar., 2009

Ph.D at Tokyo Medical University

Jun., 2011

DAIICHI SANKYO CO., LTD. TOKYO
Associate Director, Clinical Development I, R&D
Division
Associate Director, Clinical Development, DAIICHIOct., 2012

SANKYO PHARMA DEVELOPMENT, USA(CVM)(seconded)
Associate Director, Clinical Development, DAIICHIFeb., 2015

SANKYO PHARMA DEVELOPMENT, USA(Oncology)(seconded)

Oct., 2015

DAIICHI SANKYO CO., LTD. TOKYO
Associate Director, Asia Development Department,Clinical Group (Oncology)

Apr., 2019
Apr., 2020

Senior Director, Asia Development Department, ClinicalDevelopment Group
Senior Director/Group Leader, Clinical Development
Department 1, Group 2

Dec., 2021

Resigned from DAIICHI SANKYO CO., LTD. TOKYO

Jan., 2022

GE Healthcare Pharma CO., LTD. TOKYO
Head of Clinical Development Japan3

Dec., 2023
Jan., 2024
Feb., 2024

Resigned from GE Healthcare Pharma CO., LTD.
TOKYO
Joined SymBio, Head of Japan Development Division
Head of Japan Development Division and Co-Head ofGlobal BCV Business Unit
Executive Corporate Officer, Head of Japan

Mar., 2024

Development Division and Co-Head of Global BCVBusiness Unit[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

4